Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising drug cocktail aims to wipe out esophageal tumors before surgery

NCT ID NCT07505186

First seen Apr 11, 2026 · Last updated May 23, 2026 · Updated 6 times

Summary

This study tests whether giving a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) before surgery can improve outcomes for people with a type of esophageal cancer. About 45 adults with stage II to IVA esophageal squamous cell carcinoma will receive this treatment before their operation. The main goal is to see if the cancer disappears completely by the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University

    Hangzhou, China, 310009, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.